Overview

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Status:
Unknown status

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main pathological type in china patients. The investigators then initiated a prospective phase II clinical trial with irinotecan/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University

Treatments:

Camptothecin
Cisplatin
Irinotecan